Her2 and trastuzumab in breast cancer

Cancer Control

Volumn 8, Issue 1, 2001, Pages 103-110

  Horton, J ^a  

^a UNIVERSITY OF SOUTH FLORIDA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER GROWTH FACTOR; TRASTUZUMAB;

ADJUVANT THERAPY; ARTICLE; BREAST CANCER; CANCER CONTROL; CANCER REGRESSION; CANCER STAGING; DRUG SAFETY; FLUORESCENCE IN SITU HYBRIDIZATION; GENE AMPLIFICATION; GENE OVEREXPRESSION; GENE THERAPY; HEART FUNCTION; IMMUNOHISTOCHEMISTRY; ONCOGENE NEU; TUMOR CELL CULTURE;

EID: 0035128693     PISSN: 10732748     EISSN: None     Source Type: Journal    
DOI: 10.1177/107327480100800113     Document Type: Article

References (23)

1. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer
2. Assessment of methods for tissue-based detection of the HER-2/neu alteration in human breast cancer: A direct comparison of fluorescence in situ hybridization and immunohistochemistry
3. HER-2 expression and response to tamoxifen in estrogen receptor-positive breast cancer: A Southwest Oncology Group Study
4. HER-2-neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer
5. erbB-2, p53, and efficacy of adjuvant therapy in lymph node-positive breast cancer
6. First-line, non-hormonal treatment of women with HER2 overexpressing metastatic breast cancer with Herceptin (trastuzumab, humanized anti-HER2 antibody)
7. Overall survival (OS) advantage to simultaneous chemotherapy (CRx) plus the humanized anti-HER2 monoclonal antibody Herceptin (H) in HER2 overexpressing (HER2+) metastatic breast cancer (MBC)
8. The concordance between the clinical trials assay (CTA) and fluorescence in situ bybridization (FISH) in the Herceptin pivotal trials
9. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
10. Weekly (W) Herceptin (H) + 1-hr taxol (T): Phase II study in HER2 overexpressing (H2+) and non-expressing (H2-) metastatic breast cancer (MBC)
11. Herceptin and vinorelbine for HER2-positive metastatic breast cancer: A phase II study
12. Phase II trial of Herceptin induction followed by combination therapy with paclitaxel and carboplatin: A Minnie Pearl Research Network Trial
13. A phase II trial of docetaxel and Herceptin in metastatic breast cancer patients overexpressing HER-2
14. Weekly docetaxel (D) and rhumabher2 (H) combination therapy as first- or second-line treatment for metastatic breast cancer (MBC)
15. Phase II trial of weekly docetaxel (Taxotere) alone or in combination with trastuzumab (Herceptin) in patients with metastatic breast cancer
16. Elevated serum HER-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer
17. Clinical activity with the farnesyl transferase inhibitor R115777 in patients with advanced breast cancer: Relationship with tumor type
18. A phase II trial of single-agent Rhumah VEGF (recombinant humanized monoclonal antibody to vascular endothelial cell growth factor) in patients with relapsed metastatic breast cancer
19. Phase 1 trial of recombinant human anti-HER2 monoclonal antibody (H) plus low-dose interleukin-2 (IL-2) in patients with solid tumors
20. Effects of ZD1839 (Iressa), a novel EGF preceptor tyrosine kinase inhibitor on breast cancer cell proliferation and invasiveness
21. Treatment beyond progression in the Herceptin pivotal combination chemotherapy trial